Profile data is unavailable for this security.
About the company
Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.
- Revenue in CAD (TTM)0.00
- Net income in CAD-188.00k
- Incorporated2009
- Employees--
- LocationVaxil Bio Ltd3400 One First Canadian Place,TORONTO M5X 1A4CanadaCAN
- Websitehttps://vaxil-bio.com/
Mergers & acquisitions
| Acquired company | VXL:CVE since announced | Transaction value |
|---|---|---|
| Copper Bullet Mines Inc | -50.00% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hempshire Group Inc | 271.25k | -3.43m | 1.19m | -- | -- | -- | -- | 4.40 | -0.0431 | -0.0431 | 0.0034 | -0.003 | 0.1424 | 0.2852 | 29.30 | -- | -180.18 | -- | -288.91 | -- | 46.93 | -- | -1,265.05 | -- | 0.0712 | -21.61 | 1.61 | -- | -68.89 | -- | -200.59 | -- | -- | -- |
| Waverley Pharma Inc | 293.41k | -2.15m | 1.35m | -- | -- | -- | -- | 4.60 | -0.0398 | -0.0398 | 0.0054 | -0.0259 | 0.1759 | -- | 2.33 | -- | -128.84 | -32.30 | -- | -60.75 | 26.58 | 13.74 | -732.29 | -94.30 | -- | -11.66 | 5.43 | -- | -66.95 | 13.03 | -234.91 | -- | -- | -- |
| Vaxil Bio Ltd | 0.00 | -188.00k | 1.37m | -- | -- | 1.64 | -- | -- | -0.0014 | -0.0014 | 0.00 | 0.0061 | 0.00 | -- | -- | -- | -16.28 | -65.45 | -20.26 | -116.22 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 56.51 | -- | -- | -- |
| Solarvest Bioenergy Inc | 520.00 | -1.72m | 1.52m | -- | -- | -- | -- | 2,920.93 | -0.0289 | -0.0289 | 0.00001 | -0.097 | 0.0005 | -- | 0.0301 | -- | -177.23 | -95.33 | -- | -3,099.07 | 57.69 | -- | -330,076.90 | -75,194.81 | -- | -8.39 | -- | -- | -4.85 | -- | -48.35 | -- | 1.70 | -- |
